A March 28, 2018,
research note by JMP Securities analyst Michael King indicated that at the recent International Symposium on
Amyloidosis in Japan, Alnylam Pharmaceuticals Inc. (ALNY: NASDAQ) reported multiple sets
of results
of clinical trials, separately evaluating its investigational RNA interference (RNAi) therapeutics patisiran and ALN - TTRsc02.
The nature
of those plaques finally came into focus in 1984, when George Glenner, a
research scientist at the University
of California, San Diego, identified the peptide called amyloid - beta and hypothesized that Alzheimer's was caused by «
amyloidosis»
of the brain, a process in which insoluble forms
of an amyloid protein accumulate.